Spera Pharma

What Spera Pharma does

Spera Pharma (スペラファーマ株式会社) is a Japanese pharmaceutical Contract Development and Manufacturing Organization (CDMO) that was established in July 2017 as a spin-out from Takeda Pharmaceutical Company's CMC (Chemistry, Manufacturing, and Controls) research division. The company is wholly owned by Astena Holdings Co., Ltd. as a core subsidiary of the group's Fine Chemical business following its March 2020 transfer from Bushu Pharmaceuticals. Headquartered in Osaka with 249 employees as of December 1, 2025 and paid-in capital of 310 million yen, Spera Pharma operates as a privately held B2B services company targeting pharmaceutical clients across Japan, the United States, and Europe.

The company's service portfolio centers on three integrated CMC offerings: drug substance process development (asymmetric synthesis, flow chemistry, QbD-based scale-up), formulation development and manufacturing (oral and sterile injectables including Category 5 high-potency compounds), and analytical method development and quality control testing. Specialized technology differentiators include 3D ED/MicroED crystal structure analysis (commercialized as a service in April 2024), a 300+ asymmetric ligand library with commercial-scale hydrogenation capability up to 10,000L, flow chemistry for kg-scale synthesis, Xcelodose direct capsule filling, and 300+ high-sensitivity impurity methods supporting PMI control below 10 ppm. Manufacturing is delivered through the Iwaki Seiyaku Sakura Factory subsidiary, which holds tri-national GMP (Japan, US FDA, EU) and PIC/S compliance.

Spera Pharma generates revenue through project-based contracts quoted individually against client scope, with no publicly disclosed pricing or volume commitments. Its go-to-market relies on direct inquiry via website, sustained booth presence at major pharmaceutical industry exhibitions (CPHI Japan, INTERPHEX, BioJapan, Chemspec Europe, Discovery & Development Europe), dedicated webinar series, peer-reviewed publications, and direct technical consultation. The company serves global pharmaceutical companies, domestic Japanese pharma, biotech and pharma ventures, ADC and biologics developers (notably via the September 2025 strategic alliance with Mycenax Biotech), and academic institutions across a horizontal segmentation approach.

Name

Spera Pharma

Legal name

SPERA PHARMA, Inc.

Website

https://spera-pharma.co.jp

Company type

Private

Founded year

2017

Operating status

Operating

Headcount range

101–250 employees

Short description

Spera Pharma is a Japanese pharmaceutical CDMO spun out from Takeda's CMC research division in 2017, providing contract process development, formulation, analytical, and GMP-compliant manufacturing services for global pharma companies, biotech ventures, ADC developers, and academic institutions.

Ownership category

akta.pro rank

Product category

Pharmaceutical CDMO Services

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Medicinal Chemicals & Botanical Products (2833), Pharmaceutical Preparations (2834)

akta.pro primary industry

Drug Substance–Drug Product Integrated CDMO (HLAGABAG)

akta.pro secondary industries

Small-Molecule API & Intermediates CDMO (HLAGABAA), Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO (HLAGABAB), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Clinical Trial Material (CTM) Manufacturing & Supply CDMO (HLAGABAK)

Keywords

• Pharmaceutical CDMO services
• API process development
• Formulation development
• Crystal structure analysis
• GMP contract manufacturing

Headquarters

HQ city

Osaka-shi

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure

Revenue model

1. Contract R&D and Manufacturing (CDMO) Services: Full-scope CMC contract research and manufacturing services including API process development, formulation development, analytical method development, GMP manufacturing, and regulatory filing support. Revenue generated through project-based contracts with pharmaceutical clients.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels8 records

Core offering

Spera Pharma is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) providing CMC (Chemistry, Manufacturing, and Controls) research, development, and manufacturing services to pharmaceutical companies. Core offerings include API process development with asymmetric synthesis and flow chemistry, formulation development for oral and sterile injectable dosage forms, analytical method development and testing, and GMP-compliant manufacturing including high-potency injectable drug production. Services span early-stage development through regulatory filing and commercial manufacturing, supported by proprietary technologies such as 3D ED/MicroED crystal structure analysis and asymmetric catalyst libraries.

Product overview

Spera Pharma is a pharmaceutical Contract Development and Manufacturing Organization (CDMO) that provides comprehensive CMC (Chemistry, Manufacturing, and Controls) solutions from early-stage drug development through regulatory approval. The company's service portfolio centers on three core offerings: Drug Substance Process Development (including asymmetric synthesis, flow chemistry, and scale-up simulation), Formulation Development & Manufacturing (covering oral and sterile injection formulations), and Analysis & Testing Services. These core services are augmented by specialized technologies including 3D ED/MicroED Crystal Structure Analysis for advanced structural determination, Xcelodose API Direct Capsule Filling for early clinical supply, and world-top-level asymmetric catalyst technology for chiral compound development. Spera Pharma operates under tri-national GMP standards (Japan, US, EU) and PIC/S, supporting global pharmaceutical development.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug Substance Process Development API manufacturing process development from 'zero-level' considering customer's development stage, including asymmetric synthesis, flow chemistry, scale-up simulation, and process optimization based on QbD approach. Service is for pharmaceutical companies developing new drug substances from early development through commercial scale.
• Formulation Development & Manufacturing Develops oral formulations (tablets, capsules, ODT, FDC, modified release) and sterile injections (vials, lyophilized) with primary/secondary packaging capabilities. Service is for pharmaceutical companies requiring formulation development and clinical/commercial supply.
• Analysis & Testing Services Comprehensive analytical services including process analysis, method development, quality control testing, stability studies, and characterization for biopharmaceuticals using HPLC, LC/MS, NMR, and other analytical instruments. Service is for pharmaceutical companies requiring analytical support across drug development stages.
• 3D ED/MicroED Crystal Structure Analysis Cutting-edge crystal structure analysis using electron diffraction technology for analyzing extremely small crystals, crystalline powders, and mixtures that are difficult to analyze with conventional X-ray diffraction. Enables structural analysis of compounds difficult to obtain as single crystals, determination of absolute configuration, and salt/cocrystal discrimination. Service is for pharmaceutical companies needing advanced structural determination of drug substances.
• Xcelodose API Direct Capsule Filling Direct filling of APIs into capsules using two Xcelodose systems, enabling precise filling from 1mg to 100mg with minimized API loss and accelerated early clinical development. GMP-compliant weight recording. Service is for pharmaceutical companies requiring early clinical supply with small API quantities.
• Injection Manufacturing Services Clinical trial drug manufacturing including vial filling (up to 40,000 vials/batch), lyophilized formulations, and sterile fill-finish. Handles highly potent drugs (category 5) with tri-national GMP (Japan, US, EU) and PIC/S compliance. Service is for pharmaceutical companies requiring injectable drug manufacturing for clinical trials and commercial supply.
• World-top-level Asymmetric Catalyst Technology Service Comprehensive chiral technologies including asymmetric hydrogenation, chiral chromatography separation, diastereomeric salt resolution, and enzymatic resolution for chiral pharmaceutical compounds. Capabilities include asymmetric metal-catalyzed reactions, chiral column technologies for analysis and preparative HPLC, enzyme technologies with high enantioselectivity (200+ enzyme library), and commercial scale-up experience up to 10,000L. Service is for pharmaceutical companies developing chiral drug substances.
• High Sensitivity Analytical Technology Service Highly sensitive analytical techniques for controlling potential mutagenic impurities (PMIs) at ppm levels, with over 300 established analytical methods. Service is for pharmaceutical companies requiring impurity profiling and control meeting regulatory standards across global markets.

Quantifiable outcome

• 300+ highly sensitive analytical methods established for PMI control (less than 10 ppm)
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Mycenax Biotech Inc.coreStrategic or Co-development Partner · 15 September 2025Strategic alliance for antibody-drug conjugate (ADC) development and manufacturing. Combines Mycenax's end-to-end biologics capabilities with SPERA PHARMA's CMC expertise, particularly high-potency fill-finish services. Covers linker/payload synthesis, drug substance production, formulation, and aseptic fill-finish. Aims to accelerate time-to-market for biopharmaceutical companies with integrated, cost-effective ADC development platform.
• Rigaku Corporation (株式会社リガク)coreTechnology or IntegrationJoint research on 3D ED/MicroED crystal structure analysis technology. SPERA PHARMA utilizes Rigaku's electron diffraction equipment (Synergy-ED) for structural determination of pharmaceutical compounds. Collaborative publications in Crystal Growth & Design and Org. Process Res. Dev. demonstrating successful structure determination of inseparable polymorphic mixtures and nitrosamine impurities.
• Meiji Pharmaceutical UniversityminorStrategic or Co-development PartnerJoint research collaboration on novel [2+2+1] radical annulation reaction enabled by 3D ED/MicroED. Co-authored research published in The Journal of Organic Chemistry with researchers from SPERA PHARMA and Professor Nozomi Saito and Professor Masanori Tayu.
• Iwaki Seiyaku Sakura Factory Co., Ltd. (岩城製薬佐倉工場)coreOthersGroup subsidiary company operating injectable drug manufacturing facilities. Handles early, mid, late-stage clinical trial materials through commercial production including highly potent drugs. Manufacturing lines began operation in September 2023. Trilateral GMP (Japan, US, Europe) and PIC/S compliant.
• SPERA NEXUS, Inc.minorOthersAffiliated company within Astena Group providing complementary services.
• JITSUBO Co., Ltd.minorOthersGroup company engaged in pharmaceutical manufacturing. Notable collaboration includes partnership with Novo Nordisk in diabetes, obesity, and related disease areas (announced August 2023).
• Astena Holdings Co., Ltd.coreOthers100% shareholder of SPERA PHARMA. Parent company of Astena Group, a pharmaceutical group engaged in fine chemicals business. SPERA restarted as core subsidiary on March 2, 2020.

Scale indicators10 records

Recent moves9 records

Expansion highlights6 records

Direct peers

• Bushu Pharmaceuticals: Japanese CDMO that was Spera's original parent company from 2017 to 2020. Provides contract manufacturing and packaging of pharmaceuticals, offering a directly comparable Japanese mid-sized CDMO peer with overlapping oral solid dose capabilities.
• CMIC Group: Japan's largest CRO/CDMO offering integrated services from drug development through manufacturing. Comparable as a domestic Japanese mid-sized CDMO serving similar pharma customer segments with overlapping CMC, formulation, and analytical offerings.
• AGC Pharma Services: Japanese-headquartered CDMO offering API process development, formulation and GMP manufacturing for small molecules and biologics. Directly comparable mid-sized CDMO competing for similar Japanese and global pharma outsourcing contracts.
• JITSUBO Co., Ltd. Sister company under Astena Holdings engaged in pharmaceutical manufacturing with peptide-based technology. Recent Novo Nordisk partnership for diabetes/obesity; comparable as a Japan-based Astena Group CDMO peer in fine chemicals and pharmaceutical contract services.

Emerging players

• Mycenax Biotech: Taiwan-based biopharmaceutical CDMO specializing in antibody and ADC development/manufacturing. Strategic partner of Spera for ADC services, making it both a collaborator and a comparable biologics-focused CDMO peer in the same adjacent ADC value chain.

Broad incumbents

• CordenPharma: Global CDMO with strong capabilities in high-potency API and injectables manufacturing. Comparable as a broader incumbent offering overlapping sterile fill-finish, HPAPI handling, and complex formulation capabilities that compete for similar large-pharma outsourcing contracts.
• Lonza: World's largest CDMO offering API, drug product, and biologics manufacturing including microbial and cell/gene therapy. Competes with Spera for global pharma CDMO contracts and sets pricing/quality benchmarks in small molecule and complex API process development.
• WuXi STA (WuXi AppTec): Global CDMO providing API process R&D and manufacturing for small molecules. A dominant scale player whose pricing on standard API and intermediate CDMO work pressures margins for mid-sized specialists like Spera.
• Samsung Biologics: Global biopharmaceutical CDMO with large-scale biologics and ADC manufacturing capacity. Relevant broad incumbent as ADC outsourcing grows; competes with the Spera/Mycenax alliance for ADC drug substance and fill-finish contracts.
• Catalent (Novo Holdings): Global CDMO offering drug substance, drug product, and clinical supply services across modalities including oral, sterile, and biologics. A major broad incumbent whose global reach, HPAPI capabilities, and integrated services compete directly with Spera's full-chain CDMO pitch.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/spera-pharma

Compliance4 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles5 records

Subsidiaries3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Spera Pharma